Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McClellan To Lead June 13 CMS Forum On Drug Data Strategies

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and AHRQ officials will discuss ways Medicare data could help improve medical decisions. The Drug Data Strategy plan combines Part D drug data with Parts A and B medical treatment data.

You may also be interested in...

FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda

Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.

Editor's Note: Please Help Pink Sheet Serve You Best

Please take our brief reader survey to help us better understand your content and delivery needs.

Editor’s Choice: Notable Pink Sheet Articles From Q3

A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts